Latest Takeda Pharmaceutical Company Stories
Parker Waichman LLP is informing the public that generic versions of Actos (pioglitazone), which were recently approved, carry the same risks and side effects as the brand name medication. Actos is a Type 2 diabetes drug that has been repeatedly linked to bladder cancer, most recently in a study published in the Journal of the National Cancer Institute. (PRWEB) August 20, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective...
How safe are diabetes drugs? The $3 billion fine and felony guilty plea in July 2012 by the maker of Avandia, and the whistleblower lawsuit pending against the maker of Actos, raise serious safety concerns for people with diabetes, writes attorney and consumer advocate Michael J. Evans in Part 1 of a series published on ConsumerNews.com. Birmingham, AL (PRWEB) August 17, 2012 Last month the maker of Avandia, GlaxoSmithKline ("GSK") agreed with the U.S. Department of Justice to...
PRINCETON, N.J., Aug. 17, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc. Pioglitazone hydrochloride tablets is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, presently distributed by Takeda Pharmaceuticals America, Inc. under the brand...
Over 700 Actos lawsuits are pending in state court in the Circuit Court for Cook County, Illinois. Actos-Lawsuit.pro has a new article summarizing developments in the Cook County Actos litigation. Birmingham, AL (PRWEB) August 14, 2012 Over 700 Actos lawsuits are pending in Cook County Circuit Court in Chicago, Illinois. One of the many Actos lawsuit websites has just been updated to include an article about the Illinois Actos litigation, according to Attorney Michael J. Evans. Evans, one...
PARSIPPANY, N.J., Aug. 15, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding Watson's entitlement to shared exclusivity for its generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets). As a result of FDA's decision, Watson's abbreviated new drug application (ANDA) could be delayed for up to six months. Watson...
Findings of the study published on July 3rd 2012, in the Canadian Medical Association Journal, revealed that Actos (pioglitazone) is linked to increased risk of bladder cancer. Actos is a type 2 diabetes drug, manufactured by Takeda Pharmaceutical Industries Limited and promoted as decreasing insulin resistance. According to court documents, on June 12, 2012, New York resident, Wanda Heavey, filed a $10 million lawsuit in New York Eastern District Court (case no. 2:2012cv02945) alleging...
The U.S. Food & Drug Administration (FDA) Warned in June 2011 that Taking Actos for More than One Year May Increase Bladder Cancer Risks by as Much as 40%. Since then, Studies Published in the British Medical Journal and the Canadian Medical Association Journal Have Confirmed that Patients who Take Actos Over a Long Period of Time are More Likely to Develop Bladder Cancer. New York, New York (PRWEB) July 30, 2012 Public Health Watchdog, a media outlet created to inform the public...
First Actos bladder cancer lawsuit in federal Actos litigation set for trial in November 2014, Bernstein Liebhard LLP reports. New York, NY (PRWEB) July 30, 2012 Actos bladder cancer lawsuits are moving towards trial in the federal consolidated Actos litigation, In re: Actos (Pioglitazone) Products Liability Litigation (“MDL No. 2299”), Bernstein Liebhard LLP reports.* The federal multidistrict litigation is currently pending before the Honorable Rebecca Doherty in the U.S. District...
DEERFIELD, Ill. and OSAKA, Japan, July 27, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., resubmitted New Drug Applications (NDAs) to the United States (U.S.) Food and Drug Administration (FDA) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Takeda anticipates that these applications will be reviewed within the next six months....
Parker Waichman LLP has filed a lawsuit on behalf of a Kentucky woman who took Actos (pioglitazone) and developed bladder cancer, allegedly due to the diabetes drug. New York, New York (PRWEB) July 23, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Kentucky woman naming Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America,...
